| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | lenalidomide | GDSC1000 | pan-cancer | AAC | 0.073 | 0.04 |
| mRNA | clofarabine | CTRPv2 | pan-cancer | AAC | -0.06 | 0.04 |
| mRNA | BRD-A02303741:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.074 | 0.04 |
| mRNA | BRD-K13185470 | CTRPv2 | pan-cancer | AAC | 0.15 | 0.04 |
| mRNA | BRD-K13999467 | CTRPv2 | pan-cancer | AAC | -0.074 | 0.04 |
| mRNA | Genentech Cpd 10 | GDSC1000 | pan-cancer | AAC | -0.063 | 0.05 |
| mRNA | YK 4-279 | CTRPv2 | pan-cancer | AAC | -0.064 | 0.05 |
| mRNA | BRD-K66453893 | CTRPv2 | pan-cancer | AAC | -0.062 | 0.05 |
| mRNA | VX-11e | GDSC1000 | pan-cancer | AAC | 0.065 | 0.05 |
| mRNA | linifanib | GDSC1000 | pan-cancer | AAC | -0.068 | 0.05 |